References
- Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth fac-tor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029–1039.
- Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research 1995; 55: 3964–3968.
- Cross M, Claesson-Welsh L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201–207.
- Zachary I. Signalling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Cell Physiol 2001; 280: C1375–C1378.
- Sweeney C, Miller K, Sissons SE, et al. The antiangio-genic property of docetaxel is synergistic with a recombinant humanised monoclonal antibody against vascular endothelial growth factor or 2-methoxyoestradiol but antagonised by endothelial growth factors. Cancer Res 2001; 61: 3369-3372.
- Kukk E, Lymboussaki A, Taira S, et al. VEGF-C recep-tor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996; 122: 3829-3837.
- Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a phase I dose-escalating study of the ant-angiogenic agent, 5U5416, in patients with advanced malignancy. Clin Cancer Res 2003; 8: 2798-2805.
- Mendel DB, Douglas A, Xin X et al. In vivo antitumor activity of 5U11248, a novel tyrosine kinase inhibitor target-ing vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinet-ic/pharmacodynamic relationship. Clin Cancer Res 2002; 9: 327–337.
- Raymond E, Faivre S, Vera K et al. Final results of a phase I and pharmacokinetic study of 5U11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003; 22: 192 (Abstract 769).
- Demetri GD, George S, Heinrich MC et al. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor 5U11248 in patients with metastatic gastrointestinal stromal tumour (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 2003; 22: 814 (Abstract 3273).
- Rosen L, Rosen P, Kabbinavar K et al. Phase I experi-ence with 5U6668, a novel multiple receptor tyrosine kinase inhibitor in advanced solid tumours. Proc Am Soc Clin Oncol 2001; 20: 97a (Absract 383).
- Morgan B, Thomas AL, Drevs J et al. Dynamic con-trast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyro-sine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncology 2003; 21: 3955–3964.
- Sasser R, Hurwitz H, Barge A et al. Phase I pharma-cokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumours. Am Soc Clin Oncol 2001; 20: Abstract 396.
- Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angio-genesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–80.
- Fong TA, Shawyer LK, Sun L et al. 5U5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularisation and growth of multiple tumour types. Cancer Res 1999; 59: 99–106.
- Hurwitz H, Carducci MA, Robertson P et al. A phase I study of the pan-VEGFR tyrosine kinase inhibitor, CEP-7055, in patient with advanced malignancy. Proc Am Soc Clin Oncol 2003; 22: 201 (Abstract 831).
- Tolcher A, Karp D, O'Leary J et al. A phase I and bio-logical correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumours. Proc Am Soc Clin Oncol 2002; 21: 84a Abstract 334).
- Steward W, Wiedemann B, Rosewicz S et al. Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 with chemotherapy (oxaliplatin/5FU/leucovorin) in patients with advanced col-orectal cancer. Clin Cancer Res 2001; 7: 3663S, Absract 50.